RARE
Companies
NASDAQ
Ultragenyx Pharmaceutical Inc.
Health Care
$37.36
-$4.71 (-11.20%)
Price Chart
Overview
About RARE
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Market Cap
$3.4B
Volume
36.6M
Avg. Volume
38.2M
P/E Ratio
-7.309197
Dividend Yield
0.00%
Employees
1.4K
Company Information
Risk & Correlation Analysis
Market Correlation
1.09
Moderate Correlation
Volatility
High (0.40)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, RARE shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$3.4B
Volume36.6M
P/E Ratio-7.31
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 7, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025